drugset / Trial / NCT07751250
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.
Timeline
- Start
- 2026-08-14
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Casdatifan | Small molecule | 100 mg | Oral |
Indications
No indication recorded.